. "Appendix C: National Academies' Guidelines for Human Embryonic Stem Cell Research, Amended as of May 2010." Final Report of The National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to The National Academies' Guidelines for Human Embryonic Stem Cell Research. Washington, DC: The National Academies Press, 2010.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Final Report of the National Academies’ Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies’ Guidelines for Human Embryonic Stem Cell Research
Clear criteria for distribution of cell lines, including but not limited to evidence of approval of the research by an embryonic stem cell research oversight committee or equivalent body at the recipient institution.
6.0 RESEARCH USE OF hES CELL LINES
Once hES cell lines have been derived, investigators and institutions, through ESCRO committees and other relevant committees (such as an IACUC, an IBC, or a radiation safety committee) should monitor their use in research.
6.1 Institutions should require documentation of the provenance of all hES cell lines, whether the cells were imported into the institution or generated locally. The institution should obtain evidence of IRB-approval of the procurement process and of adherence to basic ethical and legal principles of procurement as described in Section 1.3(a) and 1.5. In the case of lines imported from another institution, documentation that these criteria were met at the time of derivation will suffice. Listing on the NIH Registry willbe sufficient evidence of acceptability of hES cell lines.
6.2In vitro experiments involving the use of already derived and coded hES cell lines will not need review beyond the review described in Sections 1.3(a) and 6.1.
6.3 Each institution should maintain a registry of its investigators who are conducting hES cell research and ensure that all registered users are kept up to date with changes in guidelines and regulations regarding the use of hES cells.
6.4 All protocols involving the combination of hES cells with nonhuman embryos, fetuses, or adult vertebrate animals must be submitted to the local IACUC for review of animal welfare issues and to the ESCRO committee for consideration of the consequences of the human contributions to the resulting chimeras. (See also Section 1.3(c)(iii) concerning breeding of chimeras.)
6.5 Transplantation of differentiated derivatives of hES cells or even hES cells themselves into adult animals will not require extensive ESCRO committee review. If there is a possibility that the human cells could contribute in a major organized way to the brain of the recipient animal, however,
